Review



inhibitor nc  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress inhibitor nc
    Inhibitor Nc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p2249/ELA-21/pmc11831049-110-285-327
    Average 93 stars, based on 1 article reviews
    inhibitor nc - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Transfection:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Negative Control:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Control:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Migration:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Expressing:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Small Interfering RNA:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Ligation:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    In Vivo Imaging:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Staining:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Fluorescence:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Imaging:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Injection:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Sequencing:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Western Blot:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Selection:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Luciferase:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Activity Assay:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Over Expression:

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway
    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.



    Similar Products

    inhibitor nc  (MedChemExpress)
    93
    MedChemExpress inhibitor nc
    Inhibitor Nc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p2249/ELA-21/pmc11831049-110-285-327
    Average 93 stars, based on 1 article reviews
    inhibitor nc - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    ela  (MedChemExpress)
    93
    MedChemExpress ela
    <t>ELA</t> pretreatment <t>promoted</t> <t>BMSCs</t> migration and homing. (A) Transwell migration of BMSCs in the blank and ELA pretreatment groups. (B) Wound closure of BMSCs in the blank and ELA pretreatment groups. (C) A transwell model of migration of BMSCs to damaged cardiomyocytes. (D) Transwell cell migration in different model treatment groups. (E) The wound closure of BMSCs in different model treatment groups. (F) The migration distance, velocity and forward migration index of individual cells based on the real-time migration trajectory of BMSCs by Ibidi migration model in different groups. The white/blue zone: the NRVMs culture; The red zone: the H/R-NRVMs culture; n = 30. The other experiments above were repeated three times (n = 3). Scale bar = 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation.
    Ela, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-p2249/ELA-21/pmc11831049-110-292-327
    Average 93 stars, based on 1 article reviews
    ela - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ELA pretreatment promoted BMSCs migration and homing. (A) Transwell migration of BMSCs in the blank and ELA pretreatment groups. (B) Wound closure of BMSCs in the blank and ELA pretreatment groups. (C) A transwell model of migration of BMSCs to damaged cardiomyocytes. (D) Transwell cell migration in different model treatment groups. (E) The wound closure of BMSCs in different model treatment groups. (F) The migration distance, velocity and forward migration index of individual cells based on the real-time migration trajectory of BMSCs by Ibidi migration model in different groups. The white/blue zone: the NRVMs culture; The red zone: the H/R-NRVMs culture; n = 30. The other experiments above were repeated three times (n = 3). Scale bar = 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation.

    Journal: Frontiers in Pharmacology

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway

    doi: 10.3389/fphar.2025.1541869

    Figure Lengend Snippet: ELA pretreatment promoted BMSCs migration and homing. (A) Transwell migration of BMSCs in the blank and ELA pretreatment groups. (B) Wound closure of BMSCs in the blank and ELA pretreatment groups. (C) A transwell model of migration of BMSCs to damaged cardiomyocytes. (D) Transwell cell migration in different model treatment groups. (E) The wound closure of BMSCs in different model treatment groups. (F) The migration distance, velocity and forward migration index of individual cells based on the real-time migration trajectory of BMSCs by Ibidi migration model in different groups. The white/blue zone: the NRVMs culture; The red zone: the H/R-NRVMs culture; n = 30. The other experiments above were repeated three times (n = 3). Scale bar = 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation.

    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Techniques: Migration

    ELA regulated miR-299a-5p and Exo70 expression through the APJ receptor-activated ERK1/2 pathway. (A) Transwell migration of BMSCs after silencing of APJ. (B) Scratch healing of BMSCs after silencing of APJ. (C) Polymerization of F-actin of BMSCs after silencing of APJ. (D) Expression of different proteins after silencing of APJ. (E) Diagram of possible molecular mechanisms by which ELA promoted the migration of BMSCs. All experiments were repeated at least three times (n ≥ 3). *p < 0.05, **p < 0.01, ***p < 0.001,****p < 0.0001. All miRNA expression was normalized to U6 small nuclear RNA. GAPDH serves as an internal reference protein. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation; Exo70: Exocyst complex component 7; siExo70: Exo70 small interfering RNA; p-ERK1/2: Phosphorylated extracellular regulated protein kinases1/2; t-ERK1/2: Total extracellular regulated protein kinases 1/2; APJ: Apelin receptor; siAPJ: APJ small interfering RNA; miR: MicroRNA.

    Journal: Frontiers in Pharmacology

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway

    doi: 10.3389/fphar.2025.1541869

    Figure Lengend Snippet: ELA regulated miR-299a-5p and Exo70 expression through the APJ receptor-activated ERK1/2 pathway. (A) Transwell migration of BMSCs after silencing of APJ. (B) Scratch healing of BMSCs after silencing of APJ. (C) Polymerization of F-actin of BMSCs after silencing of APJ. (D) Expression of different proteins after silencing of APJ. (E) Diagram of possible molecular mechanisms by which ELA promoted the migration of BMSCs. All experiments were repeated at least three times (n ≥ 3). *p < 0.05, **p < 0.01, ***p < 0.001,****p < 0.0001. All miRNA expression was normalized to U6 small nuclear RNA. GAPDH serves as an internal reference protein. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation; Exo70: Exocyst complex component 7; siExo70: Exo70 small interfering RNA; p-ERK1/2: Phosphorylated extracellular regulated protein kinases1/2; t-ERK1/2: Total extracellular regulated protein kinases 1/2; APJ: Apelin receptor; siAPJ: APJ small interfering RNA; miR: MicroRNA.

    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Techniques: Expressing, Migration, Small Interfering RNA

    ELA pretreatment enhanced BMSC-mediated repair of myocardial injury. (A) Surgical view following ligation of the left anterior descending branch of the coronary artery. (B) Preoperative and 1 h postoperative electrocardiograms (ECGs) of rats. (C) In vivo imaging of cells stained with DiR in various groups, along with a comparative analysis of total radiant efficiency (n = 3). (D) DiR average fluorescence imaging of the heart at 28 days after BMSCs injection via rat tail vein (n = 3). (E) An analysis of echocardiograms, specifically LVFS and LVEF results, for different treatment groups at 14 days (n = 6) and 28 days (n = 3). (F) Panoramic and localized images of HE staining in different treatment groups. (G) Panoramic and localized images of Masson staining in different treatment groups, along with analysis of the fibrosis rate (n = 4). Scale bar = 200 μm. *p < 0.05, **p < 0.01, ****p < 0.0001. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; MI/RI: myocardial ischemia-reperfusion injury; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening.

    Journal: Frontiers in Pharmacology

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway

    doi: 10.3389/fphar.2025.1541869

    Figure Lengend Snippet: ELA pretreatment enhanced BMSC-mediated repair of myocardial injury. (A) Surgical view following ligation of the left anterior descending branch of the coronary artery. (B) Preoperative and 1 h postoperative electrocardiograms (ECGs) of rats. (C) In vivo imaging of cells stained with DiR in various groups, along with a comparative analysis of total radiant efficiency (n = 3). (D) DiR average fluorescence imaging of the heart at 28 days after BMSCs injection via rat tail vein (n = 3). (E) An analysis of echocardiograms, specifically LVFS and LVEF results, for different treatment groups at 14 days (n = 6) and 28 days (n = 3). (F) Panoramic and localized images of HE staining in different treatment groups. (G) Panoramic and localized images of Masson staining in different treatment groups, along with analysis of the fibrosis rate (n = 4). Scale bar = 200 μm. *p < 0.05, **p < 0.01, ****p < 0.0001. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; MI/RI: myocardial ischemia-reperfusion injury; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening.

    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Techniques: Ligation, In Vivo Imaging, Staining, Fluorescence, Imaging, Injection

    Transcriptome screening and validation of ELA to promote cell migration. (A) Heat map and volcano plot of 99 differential genes screened by transcriptome sequencing. (B) Relative expression of Exo70 in BMSCs in blank group and ELA pretreatment group by qPCR. (C) Expression of Exo70 in BMSCs in the blank group and ELA pretreatment group by Western blotting. (D) Relative expression of Exo70 in BMSCs in different model treatment groups by qPCR. (E) Expression of Exo70 in BMSCs in different model treatment groups by Western blotting. (F) Polymerization of F-actin in two different groups. All experiments were repeated at least three times (n ≥ 3). Scale bar = 100 μm. *p < 0.05, **p < 0.01. GAPDH was used as an internal reference. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation. Exo70: Exocyst complex component 7.

    Journal: Frontiers in Pharmacology

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway

    doi: 10.3389/fphar.2025.1541869

    Figure Lengend Snippet: Transcriptome screening and validation of ELA to promote cell migration. (A) Heat map and volcano plot of 99 differential genes screened by transcriptome sequencing. (B) Relative expression of Exo70 in BMSCs in blank group and ELA pretreatment group by qPCR. (C) Expression of Exo70 in BMSCs in the blank group and ELA pretreatment group by Western blotting. (D) Relative expression of Exo70 in BMSCs in different model treatment groups by qPCR. (E) Expression of Exo70 in BMSCs in different model treatment groups by Western blotting. (F) Polymerization of F-actin in two different groups. All experiments were repeated at least three times (n ≥ 3). Scale bar = 100 μm. *p < 0.05, **p < 0.01. GAPDH was used as an internal reference. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation. Exo70: Exocyst complex component 7.

    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Techniques: Migration, Sequencing, Expressing, Western Blot

    ELA promoted BMSC migration by modulating Exo70. (A) The selection of siExo70 by qPCR. (B) The selection of siExo70 by Western blotting. (C) Transwell migration of BMSCs after silencing of Exo70. (D) Scratch healing of BMSCs after silencing of Exo70. (E) Polymerization of F-actin of BMSCs after silencing of Exo70. (F) Expression of Exo70 in BMSCs in different model treatment groups by Western blotting. All experiments were repeated at least three times (n ≥ 3). Scale bar = 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. GAPDH was used as an internal reference. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation. Exo70: Exocyst complex component 7. siExo70: Exo70 small interfering RNA.

    Journal: Frontiers in Pharmacology

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway

    doi: 10.3389/fphar.2025.1541869

    Figure Lengend Snippet: ELA promoted BMSC migration by modulating Exo70. (A) The selection of siExo70 by qPCR. (B) The selection of siExo70 by Western blotting. (C) Transwell migration of BMSCs after silencing of Exo70. (D) Scratch healing of BMSCs after silencing of Exo70. (E) Polymerization of F-actin of BMSCs after silencing of Exo70. (F) Expression of Exo70 in BMSCs in different model treatment groups by Western blotting. All experiments were repeated at least three times (n ≥ 3). Scale bar = 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. GAPDH was used as an internal reference. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation. Exo70: Exocyst complex component 7. siExo70: Exo70 small interfering RNA.

    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Techniques: Migration, Selection, Western Blot, Expressing, Small Interfering RNA

    Targeted relationship between Exo70 and miR-299a-5p. (A) Predictive map of the possible targeting relationship of Exo70 and miR-299a-5p. (B) Relative expression of miR-299a-5p in BMSCs in different treatment groups by qPCR. (C) Relative luciferase activity of different treatment groups in 293T. (D) Expression of Exo70 protein after overexpression of miR-299a-5p. All experiments were repeated at least three times (n ≥ 3). *p < 0.05, **p < 0.01, ***p < 0.001. All miRNA expression was normalized to U6 small nuclear RNA. GAPDH serves as an internal reference protein. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation; Exo70: Exocyst complex component 7; siExo70: Exo70 small interfering RNA; miR: MicroRNA.

    Journal: Frontiers in Pharmacology

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway

    doi: 10.3389/fphar.2025.1541869

    Figure Lengend Snippet: Targeted relationship between Exo70 and miR-299a-5p. (A) Predictive map of the possible targeting relationship of Exo70 and miR-299a-5p. (B) Relative expression of miR-299a-5p in BMSCs in different treatment groups by qPCR. (C) Relative luciferase activity of different treatment groups in 293T. (D) Expression of Exo70 protein after overexpression of miR-299a-5p. All experiments were repeated at least three times (n ≥ 3). *p < 0.05, **p < 0.01, ***p < 0.001. All miRNA expression was normalized to U6 small nuclear RNA. GAPDH serves as an internal reference protein. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation; Exo70: Exocyst complex component 7; siExo70: Exo70 small interfering RNA; miR: MicroRNA.

    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Techniques: Expressing, Luciferase, Activity Assay, Over Expression, Small Interfering RNA

    ELA regulated miR-299a-5p and Exo70 expression through the ERK1/2 pathway. (A) Transwell migration of BMSCs after using ERK pathway inhibitor (U0126). (B) Scratch healing of BMSCs after using U0126. (C) Polymerization of F-actin of BMSCs after using U0126. (D) The expression of different proteins after using U0126. (E) Transwell migration of BMSCs in different treatment groups. (F) Scratch healing of BMSCs in different treatment groups. (G) Relative expression of miR-299a-5p in different treatment groups by qPCR. (H) Polymerization of F-actin of BMSCs in different treatment groups. (I) The expression of Exo70 in different treatment groups by Western blotting. All experiments were repeated at least three times (n ≥ 3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. All miRNA expression was normalized to U6 small nuclear RNA. GAPDH serves as an internal reference protein. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation; Exo70: Exocyst complex component 7; siExo70: Exo70 small interfering RNA; p-ERK1/2: Phosphorylated extracellular regulated protein kinases1/2; t-ERK1/2: Total extracellular regulated protein kinases 1/2; miR: MicroRNA.

    Journal: Frontiers in Pharmacology

    Article Title: ELABELA promotes the migration and homing of bone marrow mesenchymal stem cells to myocardial injury sites through the ERK1/2/miR-299a-5p/Exo70 pathway

    doi: 10.3389/fphar.2025.1541869

    Figure Lengend Snippet: ELA regulated miR-299a-5p and Exo70 expression through the ERK1/2 pathway. (A) Transwell migration of BMSCs after using ERK pathway inhibitor (U0126). (B) Scratch healing of BMSCs after using U0126. (C) Polymerization of F-actin of BMSCs after using U0126. (D) The expression of different proteins after using U0126. (E) Transwell migration of BMSCs in different treatment groups. (F) Scratch healing of BMSCs in different treatment groups. (G) Relative expression of miR-299a-5p in different treatment groups by qPCR. (H) Polymerization of F-actin of BMSCs in different treatment groups. (I) The expression of Exo70 in different treatment groups by Western blotting. All experiments were repeated at least three times (n ≥ 3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. All miRNA expression was normalized to U6 small nuclear RNA. GAPDH serves as an internal reference protein. ELA: ELABELA; BMSCs: Bone marrow mesenchymal stem cells; H/R: Hypoxia reoxygenation; Exo70: Exocyst complex component 7; siExo70: Exo70 small interfering RNA; p-ERK1/2: Phosphorylated extracellular regulated protein kinases1/2; t-ERK1/2: Total extracellular regulated protein kinases 1/2; miR: MicroRNA.

    Article Snippet: The H/R-NRVMs medium was harvested and centrifuged at 3,000 rpm for 5 min to collect the supernatant, while NRVMs were cultured in low-glucose complete medium for 12 h. A total of 22 groups were set up with different treatments: (1) siAPJ group: BMSCs transfected with siRNA-APJ; (2) siAPJ NC group: BMSCs transfected with siRNA-APJ NC; (2) siExo70 group: BMSCs transfected with siRNA- Exo70; (4) siExo70 NC group: BMSCs transfected with siRNA- Exo70 NC; (5) mimic NC: BMSCs transfected with NC mimic; (6) miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic; (7) inhibitor NC: BMSCs transfected with inhibitor NC; (8) miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor; (9) blank group: BMSCs without any treatment (negative control); (10) ELA group: BMSCs treated with 5 μM ELA for 24 h; (11) control group: BMSCs cultured in NRVMs medium for 12 h; (12) H/R group: BMSCs cultured in H/R-NRVMs medium for 12 h; (13)H/R + ELA group: BMSCs preconditioned with 5 μM ELA and cultured in H/R-NRVM medium for 12 h; (14) H/R + ELA + siAPJ group: BMSCs transfected with siRNA-APJ before treatment with 5 μM ELA; (15) H/R + ELA + siAPJ NC group: BMSCs transfected with siRNA-APJ NC before treatment with 5 μM ELA; (16) H/R + ELA + siExo70 group: BMSCs transfected with siRNA- Exo70 before treatment with 5 μM ELA; (17) H/R + ELA + siExo70 NC group: BMSCs transfected with siRNA-Exo70 NC before treatment with 5 μM ELA; (18) H/R + ELA + mimic NC: BMSCs transfected with NC mimic before treatment with 5 μM ELA; (19) H/R + ELA + miR-299a-5p mimic: BMSCs transfected with miR-299a-5p mimic before treatment with 5 μM ELA; (20) H/R + ELA + inhibitor NC: BMSCs transfected with inhibitor NC before treatment with 5 μM ELA; (21) H/R + ELA + miR-299a-5p inhibitor: BMSCs transfected with miR-299a-5p inhibitor before treatment with 5 μM ELA. (22) H/R + ELA + U0126 group: BMSCs pretreated with 10 μM U0126 (ERK pathway inhibitor; Med Chem Express, United States) for 6 h before 5 μM ELA.

    Techniques: Expressing, Migration, Western Blot, Small Interfering RNA